Aprea Therapeutics, Inc. · NASDAQ:APRE

Aprea Therapeutics — Investor Presentation (January 2026)

29 slides from Aprea Therapeutics's investor presentation, Jan 29, 2026

  1. Slide 1: Precision Oncology Through Synthetic Lethality

    1 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Precision Oncology Through Synthetic Lethality Transforming DDR Inhibition into Patient Benefit January 2026 Confidential

  2. Slide 2: Forward-Looking Statements

    2 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Forward - Looking Statements Certain information contained in this presentation includes “forward - looking statements”, within the meaning of Section 27A of t he Securities Act of 1933, as amended, and Section 21E of the Securitie

  3. Slide 3: Our Mission: DDR, One Critical Pathway, Multiple Targets

    3 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Our Mission DDR: One Critical Pathway - Multiple Targets DNA Damage Response (DDR) 1. Ngoi N, et al . Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends in Cance r. (2021); 7(10

  4. Slide 4: Ushering in a New Phase of Precision Oncology - Synthetic Lethality

    4 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Ushering in a New Phase of Precision Oncology - Synthetic Lethality Synthetic Lethality • A clinically validated way to kill cancer 1 • Exploits tumor specific genetic weaknesses • Spares healthy cells • Biomarker driven identifica

  5. Slide 5: Oncology: A Large and Growing Market

    5 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Oncology: A Large and Growing Market Driven by Innovation and Improved Therapies • Dramatic increase in life expectancy in some cancers over past 20 years • Driven by targeted therapies and smarter combinations • Shift in perceptio

  6. Slide 6: Robust DDR Development Pipeline Milestones 2024-2026

    6 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust DDR Development Pipeline Milestones 2024 - 2026 Accomplished and anticipated clinical milestones 2026 2025 2024 H2 H1 H2 H1 H2 H1 ATR ATRN - 119 WEE1 APR - 1051 RP2D for QD dosing ACESOT - 1051: Phase 1 – Monotherapy Dose Es

  7. Slide 7: Strong Drug Development and Commercial Expertise

    7 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Strong Drug Development and Commercial Expertise Experienced team in synthetic lethality and targeted therapy Management Board of Directors Jean - Pierre Bizzari, M.D. Director Oren Gilad, Ph.D. President and CEO Richard Peters, M.

  8. Slide 8: WEE1 Inhibitor: APR-1051 ACESOT-1051: Clinical Proof-Of-Concept

    8 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 8 WEE1 Inhibitor: APR - 1051 ACESOT - 1051: Clinical Proof - Of - Concept Confidential

  9. Slide 9: WEE1 – Clinically Validated Target: An Unmet Medical Need

    9 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved WEE1 – Clinically Validated Target: An Unmet Medical Need 1. AZD - 1775. AstraZeneca announced in July 2022 the discontinuation of development of AZD - 1775 due to its tolerability profile 2. Joyce F. Liu et al., Phase II Study of

  10. Slide 10: ACESOT-1051: Phase 1 Study Design

    10 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Eligible patients ≥ 18 yo with advanced solid tumor harboring cancer - associated gene alterations CCNE1 or CCNE2 FBXW7 or PPP2R1A, KRAS - GLY12/GLY13 & TP53, and USC regardless biomarker status. HPV+ oropharyngeal squamous cell c

  11. Slide 11: APR-1051 Summary of Duration of Treatment (n=22)

    11 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 50 36 44 21 22 42 44 55 56 43 49 223 36 56 112 225 28 69 86 17 21 22 0 50 100 150 200 250 02-001 01-001 01-002 01-003 01-004 02-002 03-002 03-003 03-004 02-003 03-005 01-005 03-007 01-006 03-008 03-006 03-010 01-010 01-008 03-012

  12. Slide 12: ACESOT-1051: Encouraging Single Agent Dose Response

    12 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved ACESOT - 1051: Encouraging Single Agent Dose Response 1. >90% reduction in CA - 125 (biomarker in EC) along with unconfirmed PR ( uPR ) Endometrial Cancer (EC), Colorectal Cancer (CRC), Head and Neck Cancer (HNSCC) Clinical activi

  13. Slide 13: Treatment-related AEs in Patients Treated with APR-1051 (N=22)

    13 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Treatment - related AEs in Patients Treated with APR - 1051 (N=22) APR - 1051 All dose levels MedDRA Preferred Term Grade ≥ 3 b n (%) All Grades n (%) Treatment - related AEs a 0 (0) 6 (27.3) Nausea 0 (0) 3 (13.6) Fatigue 1 (4.5)

  14. Slide 14: Patient Example #1: Partial Response Observed in Target Indication

    14 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved From Bench to Bedside – Patient Example #1: Partial Response Observed in Target Indication and Alteration APR - 1051 shows single agent activity in cancer cells overexpressing PPP2R1A Clinical Data 150 mg Cohort Patient: 68 - year

  15. Slide 15: Patient Example #2: Preclinical Activity Observed in Early Patient Outcomes

    15 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved From Bench to Bedside – Patient Example #2: Preclinical Activity Observed in Early Patient Outcomes Pre - clinical studies with APR - 1051 Data on file APR - 1051 shows single agent activity in cancer cells overexpressing cyclin E

  16. Slide 16: Patient Example #3: Preclinical Activity Observed in Early Patient Outcomes

    16 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 'D\VVLQFHVWDUWRI[HQRJUDIW 7 XPRU 9 ROXPH PP Clinical Data 70 mg Cohort HPV+ HNSCC Mouse Model From Bench to Bedside – Patient Example #3: Preclinical Activity Observed in Early Patient Outcomes Patient: 52 - year - old Male Diagno

  17. Slide 17: HPV+ Cancer – Collaboration with MD Anderson

    17 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved HPV+ Cancer – Collaboration with MD Anderson Ovarian Cancer * UMSCC47 tumor cells OVCAR3 tumor xenograft Tumor Volume (mm 3 ) Vehicle Aprea ATRi 30 mg/kg QD Aprea WEE1i 30 mg/kg QD Combination – half dose, 15mg/kg each Days Post T

  18. Slide 18: APR-1051: Potentially Differentiated WEE1 Inhibitor Pre-Clinical

    18 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 18 APR - 1051: Potentially Differentiated WEE1 Inhibitor Pre - Clinical Confidential

  19. Slide 19: APR-1051: Potentially Best-in-Class WEE1 Inhibitor

    19 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR - 1051: Potentially Best - in - Class WEE1 Inhibitor Potent and structurally differentiated, with high selectivity to limit off - target toxicity Aprea APR - 1051 Zentalis Azenosertib (ZN - c3) AstraZeneca Adavosertib (AZD - 1

  20. Slide 20: APR-1051: Potent WEE1i That Does Not Inhibit PLK1, PLK2 or PLK3

    20 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved APR - 1051: Potentially Best - in - Class WEE1 Inhibitor Potent WEE1i that does not substantially inhibit PLK1, PLK2 or PLK3 -10 -9 -8 -7 -6 -5 -4 0 25 50 75 100 125 PLK1 IC 50 Determination Log 10 [conc] (M) % Activity ZN-c3 APR-

  21. Slide 21: PLK1 Suppression Associated with Sepsis-Induced Loss of Intestinal Barrier Function

    21 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Studies Show PLK1 Suppression is Associated with Sepsis - Induced Loss of Intestinal Barrier Function 1 PLK1 protects against sepsis - induced intestinal barrier dysfunction, Cao et al, Scientific Reports (2018). 2 PLK1 protects i

  22. Slide 22: PLK1 Inhibition Reduces Cytotoxic Effects of WEE1 Inhibitors

    22 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved PLK1 Inhibition Reduces Cytotoxic Effects of WEE1 Inhibitors 1 Minimal PLK1 co - inhibition enables full therapeutic potential of APR - 1051 37 nM 111 nM 333 nM 1 µM 37 nM 111 nM 333 nM 1 µM Phos - H2AX Control (MCM3) NT Phos - CD

  23. Slide 23: ATR Inhibitor: ATRN-119 Clinical Proof-Of-Concept

    23 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 23 ATR Inhibitor: ATRN - 119 ABOYA - 119: Clinical Proof - Of - Concept Confidential

  24. Slide 24: ABOYA-119: Phase 1/2a Trial Design and Status

    24 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved ABOYA - 119: Phase 1/2a Trial Design and Status Patient population: >12 years of age with solid tumors harboring any specific DDR mutation or Merkel Cell Carcinoma Potential Combinations • Radiation therapy • Antibody drug conjuga

  25. Slide 25: Aprea Therapeutics

    25 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Aprea Therapeutics (NASDAQ: APRE) Confidential

  26. Slide 26: Intellectual Property Portfolio, Financial Summary & Capitalization, Investment Highlights

    26 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved 26 Intellectual Property Portfolio Financial Summary & Capitalization Investment Highlights Confidential

  27. Slide 27: Robust Global Intellectual Property Protection

    27 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Robust Global Intellectual Property Protection Family 1: Ataxia Telangiectasia and Rad3 - Related (ATR) Protein Kinase Inhibitors • Macrocyclic inhibitors of ATR & methods of using them to treat various cancers, filed on Oct. 13 t

  28. Slide 28: Financial Summary & Capitalization

    28 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Common Equivalents as of November 12, 2025 Securities 15,596 Preferred Stock (as converted) 6,310,673 Common Stock (1) 507,076 1,097,394 1,097,394 2,701,864 Warrants: Pre - Funded Tranche A Tranche B Total 811,121 Options 31,008 R

  29. Slide 29: Investment Highlights: Near Term Catalysts and Cash Runway

    29 Confidential | © 2026 Aprea Therapeutics, Inc. All Rights Reserved Cash runway into Q1 2027 • Achieve near term inflection points and catalysts • Evaluate optimal strategic partnerships Near term catalysts • APR - 1051: Q1 2026 Safety/efficacy data Q3 2026 Complete dose escalation • ATRN - 119: Q

Aprea Therapeutics — Investor Presentation (January 2026) on 6ix